Early results from the use of Control-IQ™ technology showed valuable improvements in sensor time in range (TIR) and other glycemic variables for people with type 1 (T1D) and type 2 diabetes (T2D). T1D participants showed an increased sensor TIR from 67.24% to 77.07% and T2D participants showed an increase in sensor TIR from 73.93% vs 79.32%.View Poster
Percentage of Time Sensor Spent in Range
Real-world data from early adopters of Control-IQ technology demonstrate a 10% increase in median sensor time in range, without increasing hypoglycemia (sensor time <70mg/dL). Improvements in sensor time in range were consistent across age groups. Data also demonstrated a 10% decrease in sensor time above 180 mg/dL. Study participants also showed a 96% median time in closed-loop automation.View Poster
Percentage of Time Sensor Spent in Range
In the International Diabetes Closed-Loop (IDCL) Trial, Protocol 3, time in range (70-180 mg/dL)* for participants using Control-IQ technology for six months was 71% per day compared to 59% when using sensor-augmented pump (SAP) therapy alone.1View Overview
The PLGS for Reduction of Low Glucose (PROLOG) Study, showed a 31% reduction in time spent below 70 mg/dL, without rebound hyperglycemia, in participants who used the t:slim X2™ insulin pump with Basal-IQ® technology compared to those using a SAP.2View Overview
Real-world use (n=2,712) of the t:slim X2 insulin pump with Basal-IQ technology demonstrated an even greater reduction in time spent in hypoglycemia compared to outcomes observed in the PLGS for Reduction of Low Glucose (PROLOG) Study (n=102).4View Overview
In the IDCL Trial, using a 5-point scale, Control-IQ participants rated the technology a 4.7 for ease of use, 4.6 for usefulness, and 4.5 for trust.1 In the PROLOG Study, 97% of participants indicated that they felt confident using the Basal-IQ system, and 97% indicated that the system was easy to use.3
* As measured by CGM.
1. Brown SA, Kovatchev BP, Raghinaru D, et al. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. N Engl J Med. 2019;381(18):1707-17. DOI: 10.1056/NEJMoa1907863
2. Forlenza GP, Li Z, Buckingham BA, et al. Predictive low glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: Results of the PROLOG trial. Diabetes Care. 2018;41(10):2155-2161.
3. Brown S, et al. Clinical Acceptance of the Artificial Pancreas: The IDCL Trial. Poster presented at: American Diabetes Association 79th Scientific Sessions; June 9, 2019; San Francisco, CA.
4. Beck RW, et al. The association of biochemical hypoglycemia with the subsequent risk of a severe hypoglycemic event: analysis of the DCCT data set. Diabetes Technol Ther.
Important Safety Information
RX ONLY. The t:slim X2 insulin pump, Basal-IQ technology, and Control-IQ technology are intended for single patient use. The t:slim X2 pump, Basal-IQ technology, and Control-IQ technology are indicated for use with NovoLog or Humalog U-100 insulin.
t:slim X2 insulin pump: The t:slim X2 insulin pump with interoperable technology is an alternate controller enabled (ACE) pump that is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in individuals six years of age and greater. Basal-IQ technology:Basal-IQ technology is intended for use with a compatible integrated continuous glucose monitor (iCGM, sold separately) and ACE pump to automatically suspend delivery of insulin based on iCGM readings and predicted glucose values. The bolus calculator is indicated for the management of diabetes by people with diabetes by calculating an insulin dose or carbohydrate intake based on user entered data. Basal-IQ technology is intended for the management of diabetes mellitus in persons six years of age and greater. Control-IQ technology:Control-IQ technology is intended for use with a compatible iCGM (sold separately) and ACE pump to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ technology is intended for the management of Type 1 diabetes mellitus in persons six years of age and greater.
|WARNING:Control-IQ technology should not be used by anyone under the age of six years old. It should also not be used in patients who require less than 10 units of insulin per day or who weigh less than 55 pounds.|
Control-IQ technology and Basal-IQ technology are not indicated for use in pregnant women, people on dialysis, or critically ill patients. Do not use Control-IQ technology if using hydroxyurea. Users of the t:slim X2 pump, Basal-IQ technology, and Control-IQ technology must: be able and willing to use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders. The t:slim X2 pump, transmitter, and sensor must be removed before MRI, CT, or diathermy treatment. visit www.tandemdiabetes.com/safetyinfo for additional important safety information.